Aclarion, Inc.

Equities

ACON

US6551872012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.337 USD -14.18% Intraday chart for Aclarion, Inc. +12.52% -89.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Midday Decliners MT
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Decliners MT
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast MT
US Futures Nudge Lower in Friday's Premarket Ahead of Fed Inflation Data MT
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index MT
Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution CI
Top Midday Gainers MT
Aclarion and Atec Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan CI
Aclarion to Implement 1-for-16 Reverse Stock Split; Shares Rise MT
Aclarion, Inc. announced that it has received $0.25 million in funding CI
Aclarion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aclarion to Form Partnership With Alphatec Holdings Unit to Accelerate Marketing of Nociscan MT
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan CI
Aclarion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aclarion Files Registration Statement on Behalf of Selling Stockholders MT
Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aclarion Signs Commercial Deal With Michigan Medical Imaging Center MT
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aclarion, Inc. Auditor Raises 'Going Concern' Doubt CI
Aclarion, Inc. George Frey MD as Key Opinion Leader CI
Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD CI
Aclarion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Certain Common Stock of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2022. CI
Certain Warrants of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2022. CI
Chart Aclarion, Inc.
More charts
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.337 USD
Average target price
1.5 USD
Spread / Average Target
+345.10%
Consensus